TrialScientific reports2019

Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.

Gamal Shiha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.